

60 Market Center Dr. #103, Collierville, TN 38017 O: 901.316.5752 TP: 855.344.8724 F: 901.316.5760 TF: 844.588.5560 beneverepharmacy.com

TODAY'S DATE:	
☐ NEW PATIENT	CURRENT PATIENT

Inflammatory Arthritis and Osteoporosis Referral Form

	PATIENT INFORMAT	TON	PRI	ESCRIBER INFORMATION		
tient Name			Prescriber Name	DEA		
dress			NPI#	Tax ID		
		e ZIP				
				0		
	551	I 1ale □ Female		State Fax		
		INSURANCE, MEDICA	ARE OR MEDICAID INFORMATION			
	nce		Secondary Prescription Insurance (if ap			
	Group			Group		
			NSURANCE, PRESCRIPTION AND/OR CO-PAY ASSI			
		CLINIC	CAL INFORMATION			
			Patient weight	= :	□ Yes □ N	
evious biologic ently on a biologic?	Yes □ No How long?		Other This Rx is:	☐ New therapy ☐ Continuing previous treatm	ent on this a	
	DRUG NAME	DIRE	CTIONS FOR USE (PLEASE CHECK ONE OR MORE)	QUANTITY	REFIL	
Actemra® 162mg Prefille	ed Syringe	□ < 100kg, Inject 162mg subcutaneo □ ≥ 100kg, Inject 162 mg subcutaneo				
Cimzia® 200mg Prefilled	Syringe	☐ Induction : Inject 400 mg subcutan	neously on day 1, week 2, and week 4			
		☐ Maintenance: Inject 200mg subcu ☐ Maintenance: Inject 400mg subcu				
□ Cosentyx® □ 150mg Sensoready Pen		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	_mg subcutaneously at weeks 0,1,2,3, and 4	35 Day Supply	0	
☐ 150mg Prefilled Syringe	☐ Maintenance: Inject	mg subcutaneously every 4 weeks	28 Day Supply			
Enbrel® 25mg □ 50mg	☐ Sureclick Autoinjector ☐ Prefilled syringe ☐ Mini	☐ Inject subcutaneously weekly☐ Other				
Forteo®	☐ Pen and Supplies	☐ Inject 20mcg subcutaneously daily	у			
Humira® Humira® Citrate Free	☐ Pens (40mg) ☐ Prefilled syringe		☐ Inject 20mg subcutaneously every other week ☐ Inject 40mg subcutaneously every other week			
Kevzara® 150mg □ 200mg	☐ Prefilled Syringe ☐ Pen	☐ Inject 1 syringe subcutaneously e	□ Inject 1 syringe subcutaneously every other week			
Olumiant®	☐ 2mg Tablet	☐ One tablet once daily		30 Day Supply		
Orencia®	☐ 250mg Vial ☐ 125mg Prefilled syringe ☐ 125mg ClickJect	☐ Infusion: Initial dose ☐ Subcutaneous: Inject 125mg subc	mg intravenously (no refill) utaneous weekly (first dose, one day after infusion)			
□ Otezia® □ St D:		Day 3 - 10mg in AM/20mg in PM, D	Starter Pack: Take as follows: Day 1 - 10mg in AM, Day 2 - 10mg in AM/10mg in PM, Day 3 - 10mg in AM/20mg in PM, Day 4 - 20mg in AM/20mg in PM, Day 5 - 20mg in AM/30mg in PM, Day 6 and after 30mg twice daily		0	
		☐ Maintenance: Take 30mg by mout	□ Maintenance: Take 30mg by mouth twice a day.			
			□ Bridge: Take 30mg by mouth twice a day, dispensed by OSP.			
Otrexup®	☐ 10mg ☐ 12.5mg ☐ 15mg ☐ 17.5mg ☐ 20mg ☐ 22.5mg ☐ 25n		Inject 1 pen subcutaneously every week			
Prolia®	•	☐ Inject 60mg subcutaneously once	every 6 months			
Rasuvo®	☐ 7.5mg ☐ 10mg ☐ 12.5mg ☐ 15mg ☐ 17.5mg ☐ 20mg ☐ 22.5mg ☐ 25mg ☐ 27.5mg ☐ 30mg	Inject 1 pen subcutaneously every w				
Simponi® 50mg/0.50ml	☐ SmartJect™ ☐ Prefilled syringe	☐ Inject 50mg subcutaneously ever	y 4 weeks			
□ Stelara® □ ≤100kg, Inject 45 mg subcutaneously da		ısly day 1, week 4, and then every 12 weeks	28 Day Supply	0		
		□ >100kg, Inject 90 mg subcutaneou	ısly day 1, week 4, and then every 12 weeks	84 Day Supply		
Tymlos®	☐ Pen and Supplies	☐ Inject 80mcg subcutaneously daily	y.			
Xeljanz®		☐ Take 5mg tablet twice daily		30 Day Supply		
Xeljanz XR ®		☐ Take 11mg tablet once daily				
iver to: Patient's Ho Physician's Ist dose to N		☐ Physician's	s received injection training 's office to provide injection training to coordinate injection training			
escriber's Signatur	re (signature required. NO S	ΔMPS)		Date		
_	= '		ation designated agent in dealing with medical and prescriptio			

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged, proprietary or exempt from disclosure under applicable law If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.